Drugs for COVID-19: An Update

Molecules. 2022 Dec 5;27(23):8562. doi: 10.3390/molecules27238562.

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was the seventh known human coronavirus, and it was identified in Wuhan, Hubei province, China, in 2020. It caused the highly contagious disease called coronavirus disease 2019 (COVID-19), declared a global pandemic by the World Health Organization (WHO) on 11 March 2020. A great number of studies in the search of new therapies and vaccines have been carried out in these three long years, producing a series of successes; however, the need for more effective vaccines, therapies and other solutions is still being pursued. This review represents a tracking shot of the current pharmacological therapies used for the treatment of COVID-19.

Keywords: COVID-19; JAKs inhibitors; NSAIDs; SARS-CoV-2; antibiotics; anticoagulants; antivirals; immunomodulators; interleukin inhibitors.

Publication types

  • Review

MeSH terms

  • COVID-19*
  • China
  • Humans
  • Pandemics / prevention & control
  • SARS-CoV-2
  • Vaccines*

Substances

  • Vaccines

Grants and funding

This work was supported by the Italian Ministry of University and Research (MUR, D.M.1062 del 10.08.2021)-PON R&I 2014–2020 Azione IV.6 “Contratti di Ricerca su Tematiche Green” 1062_R13_GREEN (J.C.); PRIN (Progetti di Rilevante Interesse Nazionale) Grant 2017M8R7N9_004 and 2020KSY3KL_005 from MUR, Italy (S.A.) and Project HORIZON EUROPE SEEDS ID S17 “Tutela della libertà e contrasto delle pandemie. Scienza e diritto per la definizione delle strategie per il contenimento delle situazioni di contagio”—NextgenerationEU Programma MUR—Fondo promozione e sviluppo—DM 737/2021 (A.C.).